Turing Pharmaceuticals founder Martin Shkreli, who was recently found guilty on two counts of securities fraud and one count of conspiracy to commit securities fraud, is helping launch a startup to test beta technologies for legal research, pharmaceutical research and finance, reports CNBC.
Here are five things to know.
1. According to Mr. Shkreli's LinkedIn profile, the company, called Gödel Systems, was founded in August 2016.
2. Gödel Systems claims to be a New York City-based software company which hopes to become a "leading information provider of data, workflow and communications solutions for financial, law and scientific professionals," reads its website.
3. According to the Internet Archive, the site posted only the words "Coming Soon" as of June 3, reports CNBC. It now lists full team and product descriptions, and potential customers can request product demos.
4. Mr. Shkreli is listed as the startup's co-founder and CEO, while Ralph Holzmann, a former Twitter engineer, is listed as chief technology officer.
5. The company declined comment to CNBC.
Mr. Shkreli is famous for a 2015 drug markup scheme, in which his company, Turing Pharmaceuticals, raised the price on a life saving drug by more than 5,000 percent.
More articles on health IT:
Study: HITECH Act drove EHR adoption
Groove Health raises $1.6M for medication adherence platform